Alto Neuroscience (ANRO) said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo.
"Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker," Alto Neuroscience said.
ALTO-100 is also being evaluated as an adjunctive treatment in a phase 2b study for bipolar depression, the company said.
Alto expects its current cash position to fund planned operations into 2027 and through multiple upcoming clinical readouts.
Shares of the company plunged 60% in after-hours activity on Tuesday.
Price: 5.82, Change: -8.71, Percent Change: -59.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.